



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :

A61K 38/16, 47/00, 47/18, 47/26, 47/42

A1

(11) International Publication Number:

WO 97/35604

(43) International Publication Date:

2 October 1997 (02.10.97)

(21) International Application Number: PCT/US96/14756

(22) International Filing Date: 16 September 1996 (16.09.96)

(30) Priority Data:

08/624,771

27 March 1996 (27.03.96)

US

(71) Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; 614 Walnut Street, Madison, WI 53705 (US).

(72) Inventors: JOHNSON, Eric, A.; 3901 Council Crest, Madison, WI 53711 (US). GOODNOUGH, Michael, C.; 2097 Spring Road, Stoughton, WI 53589 (US).

(74) Agents: KRYSHAK, Thad et al.; Quarles & Brady, 411 East Wisconsin Avenue, Milwaukee, WI 53202-4497 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: PHARMACEUTICAL COMPOSITIONS OF BOTULINUM TOXIN OR BOTULINUM NEUROTOXIN AND METHODS OF PREPARATION

(57) Abstract

Lyophilized pharmaceutical compositions containing botulinum toxin or botulinum neurotoxin and effective amounts of trehalose and methionine have a shelf life of up to 4 months or more at room temperature and above.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PHARMACEUTICAL COMPOSITIONS OF BOTULINUM TOXIN OR
BOTULINUM NEUROTOXIN AND METHODS OF PREPARATION

Field of the Invention

The present invention generally relates to botulinum toxin. More particularly, it relates to novel storage stable, lyophilized, pharmaceutical compositions containing
5 either botulinum toxin or botulinum neurotoxin and methods for preparing such compositions.

Background of the Invention

The most serious form of bacterial food poisoning is botulism which is caused by neurotoxins produced by
10 *Clostridium botulinum*. The toxins are usually preformed by the causative organism in foods and subsequently absorbed through the intestinal tract and transported via the circulatory system to motor nerve synapses where their action blocks normal neural transmissions. Various serotypes of *C.*
15 *botulinum* produce neurotoxins with similar toxic activity but which differ antigenically. Serotype A toxin is the predominant cause of botulism in the United States while type B toxin is the most prevalent in Europe.

Crystalline type A botulinum toxin complex was prepared
20 in 1979 by E. J. Schantz of the Food Research Institute/ Department of Food Microbiology and Toxicology at the University of Wisconsin-Madison, U.S.A. It has been used medically to treat hyperactive muscle disorders such as strabismus, blepharospasm, and spasmodic torticollis.
25 Treatment involves injection of nanogram quantities of toxin directly into the hyperactive muscles. The toxin inhibits the release of acetylcholine across the synaptic junction causing a decrease in activity of the injected muscles.

A major drawback to using commercially available
30 botulinum toxin complex preparations for the treatment of hyperactive muscle and other conditions is the development of antibodies or other types of immunity by patients. Proteins of the toxin complex are recognized by patient's immune systems as foreign and they stimulate antibody production.
35 This renders treatment of the various hyperactive muscle

-2-

disorders with botulinum toxin ineffective. One way to reduce the number of patients developing neutralizing antibodies is to use the purified neurotoxin. Another way would be to have a more shelf-stable product which has a higher specific activity following lyophilization because less of the active protein is denatured. Such a product would not be as antigenic as the currently available product and lesser quantities would be required for treatment.

Botulinal toxin is very susceptible to denaturation due to surface denaturation, heat, and alkaline conditions. Lyophilization or freeze-drying of the toxin complex or the neurotoxin is the most economically sound and practical method of distributing the product in a form that is stable and readily used by the clinician. The current commercial type A botulinal toxin product is made by combining up to 500 ng/ml of type A toxin complex in 5.0 mg/ml human serum albumin (HSA) with 9.0 mg/ml sodium chloride at a pH of 7.3. After dissolution, 0.1 ml is dried to obtain 100 ± 30 active U of toxin, 0.5 mg of HSA, and 0.9 mg of sodium chloride per vial. This product has a saline concentration of 0.9% when reconstituted in 1.0 ml of dH_2O . The current commercial formulation which employs the toxin complex has a specific toxicity of about 2.5 U/ng after drying. The considerable loss (up to 90%) of activity during drying causes the formation of inactive toxin that serves as a toxoid inciting antibody formation. The current commercial product must be stored at a temperature of -10°C or less to maintain the labelled potency for the one year shelf life.

Type A neurotoxin produced by *C. botulinum* is present in the toxin as part of a complex of at least seven different noncovalently bound proteins. The neurotoxin is more active than the toxin complex. High quality type A toxin complex has a specific toxicity of 3×10^7 mouse intraperitoneal 50% lethal doses (LD_{50}) per mg. The purified neurotoxin, that is the neurotoxin that has been chromatographically separated from the other proteins of the toxin complex, has a specific toxicity of 9×10^7 to 1×10^8 LD_{50} per mg. In the medical field, a unit (U) is considered to be 1 LD_{50} . Toxin titers

are determined in female, white mice, 18-22g in weight according to the method of Schantz and Kautter as described in Association of Official and Analytical Chemistry, vol. 61, p. 96, (1978).

5 A rabbit model in which repetitive injections of various type A toxin preparations have been given to simulate the treatment of a focal dystonia has been used to assess the immunogenicity of various toxin preparations. The model consists of injecting albino rabbits with sub-lethal doses of
10 the toxin over a period of time and assaying the serum of the animals for the ability to neutralize a small but carefully quantitated amount of purified type A toxin. Our results show that the product presently available in the United States which has the lowest specific toxicity of all
15 preparations tested is the most antigenic of all the preparations tested to date. These results indicate that high specific activity preparations reduce the probability of patients developing neutralizing antibodies. It obviously would be desirable to have higher specific activity
20 preparations than those currently available.

 We previously discovered that pharmaceutical compositions made from an aqueous pre-lyophilization formulation containing essentially pure botulinum type A neurotoxin, human serum albumin (HSA), and trehalose provided
25 for the improved recovery of active toxin following lyophilization (>80%). The use of the pure neurotoxin instead of the toxin complex, which is used commercially, reduced the amount of toxin required to obtain the necessary number of active U per vial as mandated by the U.S. Food and Drug
30 Administration. This improvement also reduces the amount of inactive toxin (toxoid) in each vial and thereby lessens the possibility of antibody formation after injection of the preparation into patients.

 We also previously discovered that the compositions
35 obtained by adding trehalose to the pre-lyophilization formula had an increased shelf life at higher storage temperatures (e.g., up to 6 months at 37°C).

Brief Summary of the Invention

We have now discovered that shelf life of a lyophilized botulinum toxin or neurotoxin containing composition can be improved by the addition of a denaturation preventing amount of a thioalkyl amino acid, such as methionine or cysteine, to an aqueous pre-lyophilization formulation containing botulinum toxin or neurotoxin, a stabilizing protein, such as albumin, and a polysaccharide sugar, such as trehalose. The addition of methionine has increased the shelf-stability of the compositions at temperatures of 42°C for up to 3 months or more.

Description of Preferred Embodiment

The preferred pharmaceutical composition of the present invention is a lyophilized solid in a 10 ml glass vial which has the following composition:

Botulinum Type A Neurotoxin, 100 U
Methionine, 1 mg/vial
Trehalose, 10 mg/vial
Serum albumin, 0.5 mg/vial

The preferred composition is prepared from a liquid pre-lyophilization formulation containing the same concentrations of the neurotoxin, serum albumin, trehalose and methionine in water.

The Hall A strain of type A *C. botulinum* (deposited with the ATCC) is used to produce the preferred type A neurotoxin. This strain is routinely used for production of type A botulinum toxin due to high toxin titers and the rapid onset of cell lysis (usually within 48 h).

For toxin production, cultures of the Hall A strain are grown statically in 10-20 liter volumes of toxin production medium (TPM) consisting of 2.0% NZ amine or TT (Sheffield Laboratories, Norwich, NY), 1.0% yeast extract (Difco), and 0.5% dextrose, pH 7.37.4, for 5-7 days at 37°C.

To prepare essentially pure type A neurotoxin, the type A toxin complex is first purified according to the method described in the Ph.D. thesis of M. C. Goodnough (Goodnough, M.C. 1994, Characterization and stabilization of *Clostridium*

-5-

botulinum toxin for medical use. Ph.D. thesis, UW-Madison, as adapted from Tse et al. 1982)

Type A neurotoxin is purified from the associated non-toxic proteins of the complex by a modification of the method of Tse et al. (1982) (Goodnough, M.C., 1994, Thesis, University of Wisconsin-Madison, U.S.A.). Toxin complex is recovered from the DEAE-Sephadex A50 (Sigma Chemical Co., St. Louis, MO U.S.A), pH 5.5, column and is precipitated by addition of 39 g of solid ammonium sulfate/100ml. The precipitated toxin complex is collected by centrifugation, dialyzed against 25 mM sodium phosphate, pH 7.9, and applied to a DEAE-Sephadex A50 column equilibrated with the same buffer. Toxin is separated from the non-toxic proteins of the complex and eluted from the column with a linear 0-0.5M sodium chloride gradient. Partially purified neurotoxin is recovered from the DEAE-Sephadex A50 column at pH 7.9 and dialyzed against 25 mM sodium phosphate, pH 7.0. The dialyzed toxin is applied to SP-Sephadex C50 (Sigma Chemical Co.) in 25 mM sodium phosphate, pH 7.0. Contaminating material does not bind to the column under these conditions. The neurotoxin is eluted with a linear 0-0.25 M sodium chloride gradient. The neurotoxin can be further purified by metal affinity chromatography, gel filtration or other methods of protein chromatography.

For lyophilization, the pre-lyophilization formulation is placed in glass vials with Teflon lined screw cap closures fastened loosely, and the samples are quickly frozen in liquid nitrogen. The frozen samples are placed into a lyophilization flask which is then immersed in liquid nitrogen. When the pressure drops below ca. 60 mTorr, the liquid nitrogen jacket is removed. Pressure is maintained at or below 30-60 mTorr and condenser temperature constant at -60°C. The vials and their contents are allowed to come to room temperature and drying continued at ambient temperature over the next 18-24 h. At that time the flask is removed and the vials tightly capped.

Vials of lyophilized product made from the described pre-lyophilization formulation containing methionine and

-6-

identical formulations not containing methionine were stored at various temperatures to investigate the effect of the methionine on the shelf-stability of the lyophilized product. In these cases, the tightly capped vials were placed into plastic bags, sealed and stored at various temperatures (-20, 4, 37 or 42°C) and the contents assayed for toxicity at various time points. The lyophilized preparations were then reconstituted in 1.0 ml of distilled water. The use of 0.85% saline for reconstitution gave equivalent results. The resulting solutions were transparent and contained no particulates. These solutions were titrated by the same method used for the pre-lyophilization formulation.

The percent recovery of activity (calculated as number of mouse intraperitoneal lethal doses per vial after lyophilization divided by the number of mouse intraperitoneal lethal doses before lyophilization X 100) following lyophilization of different type A and B neurotoxin formulations are shown in Table 1.

TABLE 1

	<u>Excipient/Starting toxin neurotoxin type^a</u>	<u>concentration^b</u>	<u>pH</u>	<u>percent recovery^c</u>
20	1. bovine serum albumin/type A	200	6.4	90
	2. bovine serum albumin/type B	100	6.4	80
	3. human serum albumin/type A	1,000	6.4	90
25	4. human serum albumin/type B	100	6.4	90
	5. bovine serum albumin, trehalose/type A	500	5.7	>90
	6. bovine serum albumin, maltotriose type A	250	7.0	90
30	7. bovine serum albumin, methionine/type A	250	6.8	90
	8. bovine serum albumin, trehalose, methionine/type A	250	6.8	90

35 ^a concentrations were as follows bovine and human serum albumin - 9.0 mg/ml, carbohydrate - 100 mg/ml in all cases, and methionine - 10 mg/ml;

^b mouse intraperitoneal lethal doses/vial;

40 ^c (number of mouse lethal doses/vial after lyophilization ÷ number of mouse lethal doses before lyophilization) x 100 immediately following lyophilization.

- 7 -

The primary advantages of the preferred compositions of the present invention are their high percentage recovery of biologically active neurotoxin and long-term stability (shelf life) for up to and exceeding three months at temperatures as high as 37°C to 42°C. In contrast, current commercial product must be stored at temperatures of -10°C or less.

The exact mechanism by which the methionine further improves the shelf life of the compositions containing trehalose is not known. However, improvement does appear to be linked to presence of the thioalkyl group in the amino acid. Table 2 shows recovery of activity following storage of lyophilized type A neurotoxin products at different temperatures.

TABLE 2

Excipient combination from Table 1	Storage Temperature	Days of storage	Percent recovery ^a
1. BSA alone	-20°C	10	90
		60	90
		125	90
5. BSA + trehalose	4°C	60	90
		100	50
		125	25
7. BSA + methionine	37°C	15	75
		60	50
		125	25
8. BSA + trehalose + methionine	4°C	60	75
		100	75
		125	75
9. BSA + trehalose + methionine	37°C	60	90
		100	90
		125	90
10. BSA + trehalose + methionine	25°C	15	75
		30	50
		60	50
11. BSA + trehalose + methionine	37°C	15	75
		30	50
		60	25
12. BSA + trehalose + methionine	42°C	15	50
		30	25
13. BSA + trehalose + methionine	25°C	15	90
		30	90
		60	90
14. BSA + trehalose + methionine	37°C	15	90
		30	90
		60	90
15. BSA + trehalose + methionine	42°C	15	90
		30	90
		60	90

^a (number of mouse lethal doses/vial after lyophilization and storage under given conditions listed ÷ number of mouse lethal doses before lyophilization) x 100

In addition to type A, there are six other serotypes of the botulinum toxin with similar toxic activity but which differ antigenically. They are type A, B, C, D, E, F and G. Type A is the predominant toxin in cases of botulism in the United States, and type B toxin is most prevalent in Europe. The symptoms for the disease caused by the various serotypes are about the same. Therefore, in some instances it may be desirable to use one of the other serotypes in the pharmaceutical compositions of the present invention.

10 The preferred polysaccharide sugar is trehalose. However, in some cases other sugars such as maltotriose can be used. The amount of trehalose to be used is preferably from about 10 mg to about 150 mg per ml of the pre-lyophilized liquid formulation. Especially preferred is the use of about 15 100 mg/ml.

 The preferred thioalkyl amino acid is methionine; however, in some cases it may be desirable to use cysteine. The amount of methionine which is effective to prevent denaturation of the compound having botulinum toxicity is 20 preferably from about 1 mg to about 10 mg per ml of the pre-lyophilized formulation. Especially preferred is the use of about 10 mg of methionine per ml.

 The antigenicity of various toxin preparations (containing low or high specific toxicities) was evaluated in 25 rabbits by repetitive injection of sublethal doses of toxin simulating treatment of a focal dystonia with botulinal toxin. The samples were standardized to contain the same number of active lethal doses in order that the immune response from the rabbits could be compared.

30 Total toxin concentration for each preparation (i.e. both active and inactive) was determined using an enzyme-linked immunosorbent assay (ELISA) specific for type A botulinal toxin.

 Other test results show that the immune response of 35 rabbits to botulinal toxin is dependent on concentration of the toxin (active + inactive) injected as well as the number of times the animal is exposed to that concentration. From these results it follows that the higher the specific activity

of the lyophilized/reconstituted toxin product, the less antigenic material the patient is exposed to for a given dosage and the smaller the chances of patients developing neutralizing antibodies. Thus, it is preferred to have
5 lyophilized pharmaceutical compositions of essentially pure neurotoxin which permit the recovery of a high percentage of the starting activity and which contain trehalose and methionine so that they can be stored at room temperature or higher for up to 3 months or more.

10 It will be apparent to those skilled in the art that a number of modifications and changes can be made without departing from the spirit and scope of the present invention. Therefore, it is intended that the invention be limited only by the claims.

-10-

We claim:

1. A lyophilized solid pharmaceutical composition comprising:

- (a) a compound having botulinum toxicity;
- (b) a stabilizing protein;
- 5 (c) a polysacchride sugar; and
- (d) a thioalkyl compound;

said thioalkyl compound being present in an amount effective to prevent the denaturation of the compound at room temperature or above.

2. A composition of claim 1 in which the stabilizing protein is human serum albumin.

3. A composition of claim 1 in which the thioalkyl compound is selected from methionine and cysteine.

4. A composition of claim 1 in which the polysaccharide sugar is trehalose.

5. A composition of claim 1 in which the compound having botulinum toxicity is type A botulinum neurotoxin.

6. A composition of claim 1 in which the compound having botulinum toxicity is type A botulinum toxin complex.

7. A lyophilized solid pharmaceutical composition of botulinum neurotoxin which is stable at room temperature for up to four months without losing potency, said composition comprising pure type A botulinum neurotoxin and effective
5 amounts of trehalose and methionine to increase the storage stability of the composition at room temperature.

8. A method of preparing a lyophilized solid composition of claim 1 which comprises preparing a pre-lyophilization formulation containing a member having botulinum toxicity, a stabilizing protein, a polysaccharide sugar, a thioalkyl
5 compound and water and then lyophilizing the formulation to remove the water and obtain the lyophilized solid composition.

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K38/16 A61K47/00 A61K47/18 A61K47/26 A61K47/42

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 00481 A (ASSOCIATED SYNAPSE BIOLOGICS) 6 January 1994 see the whole document ---	1-8
A	EP 0 593 176 A (WISCONSIN ALUMNI RESEARCH FOUNDATION) 20 April 1994 see the whole document ---	1-8
A,P	WO 96 11699 A (WISCONSIN ALUMNI RESEARCH FOUNDATION) 25 April 1996 see the whole document -----	1-8

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

5 February 1997

Date of mailing of the international search report

11.02.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Scarponi, U

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9400481	06-01-94	AU-A- 4646393	24-01-94
		CA-A- 2138020	06-01-94
		EP-A- 0654040	24-05-95
		JP-T- 8506083	02-07-96

EP-A-593176	20-04-94	JP-A- 6192118	12-07-94

WO-A-9611699	25-04-96	US-A- 5512547	30-04-96
		AU-A- 2777795	06-05-96
